Clinical implications of studies with MnDPDP in animal models of hepatic abnormalities

Acta Radiologica

Volumn 38, Issue 4 PART 2, 1997, Pages 724-731

  Ni, Yicheng ^a   Marchal, G ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Contrast media, manganese; Experimental; Hepatic dysfunction, MR imaging; Liver neoplasms, cholestasis; Mangafodipir trisodium

Indexed keywords

CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; EDETIC ACID; MANGANESE; N,N' BIS(PYRIDOXAL 5 PHOSPHATE)ETHYLENEDIAMINE N,N' DIACETIC ACID; N,N'-BIS(PYRIDOXAL-5-PHOSPHATE)ETHYLENEDIAMINE-N,N'-DIACETIC ACID; PYRIDOXAL 5 PHOSPHATE;

ANIMAL; DISEASE MODEL; DRUG SCREENING; HUMAN; LIVER; LIVER DISEASE; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; REVIEW;

ANIMALS; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EDETIC ACID; HUMANS; LIVER; LIVER DISEASES; MAGNETIC RESONANCE IMAGING; MANGANESE; PYRIDOXAL PHOSPHATE;

EID: 0031180050     PISSN: 02841851     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841859709172405     Document Type: Article

References (42)

1. BERNARDINO M. E., YOUNG S. W., LEE J. K. T. & WEINREB J. C.: Hepatic MR imaging with Mn-DPDP. Safety, image quality, and sensitivity. Radiology 183 (1992), 53.
2. CHEZMAR J., REDVANLY R. D. & SEWELL C. W.: Uptake of mangafodipir trisodium (MnDPDP) by hepatocellular carcinoma. Correlation with unenhanced imaging findings and histopathologic features. Acad. Radiol. 3 (1996), S413.
3. COLEY B. D., MATTREY R. F., BAKER K. G., PETERSON T. & BRGAN A. R.: MR imaging assessment of experimental hepatic dysfunction with Mn-DPDP. J. Magn. Reson. Imaging 5 (1995), 11.
4. ELIZONDO G., FRETZ C. J., STARK D. D. et al.: Preclinical evaluation of Mn-DPDP. New paramagnetic hepatobiliary contrast agent for MR imaging. Radiology 178 (1991), 73.
5. GRANT D., HOLTZ E. & ZECH K.: Biodistribution and in vivo stability of manganese dipyridoxyl-diphosphate in relation to imaging efficacy. Invest. Radiol. 29 (1994), S249.
6. GRANT D., TOFT K. G., MARTINSEN I. & ATZPODIEN E.: Tissue distribution and general safety of MnDPDP in male beagle dogs, with or without total common bile duct obstruction. Acta. Radiol. 38 (1997), 732.
7. HAMM B., VOGL T. J., BRANDING G. et al.: Focal liver lesions. MR imaging with Mn-DPDP - Initial clinical results in 40 patients. Radiology 182 (1992), 167.
8. HUSTVEDT S. O., GRANT D., SOUTHON T. E. & ZECH K.: Plasma pharmacokinetics, tissue distribution and excretion of MnDPDP in the rat and dog after intravenous administration. Acta. Radiol. 38 (1997), 690.
9. KLAASSEN C. D.: Biliary excretion of manganese in rats, rabbits and dogs. Toxicol. Appl. Pharmacol. 29 (1974), 458.
10. KREFT B. P., TANIMOTO A., BABA Y., ZHAO L., FINN J. P. & STARK D. D.: Enhanced tumor detection in the presence of fatty liver disease. Cell-specific contrast agents. J. Magn. Reson. Imaging 4 (1994), 337.
11. DE LAMIRANDE E. & PLAA G. L.: Dose and time relationship in manganese-bilirubin cholestasis. Toxicol. Appl. Pharmacol. 49 (1979), 257.
12. DE LAMIRANDE E. & PLAA G. L.: Role of manganese, bilirubin and sulfobromophtalein in manganese-bilirubin cholestasis in rats. Proc. Soc. Exp. Biol. Med. 158 (1978), 283.
13. LEANDER P., GOLMAN K., KLAVENESS J., HOLTZ E., OLSSON M. & LEUNSACH I. B.: MRI contrast media for the liver. Efficacy in conditions of acute biliary obstruction. Invest. Radiol. 25 (1990), 1130.
14. LIM K. O., STARK D. D., LEESE P. T., PFEFFERBAUM A., ROCKLAGE S. M. & QUAY S. C.: Hepatobiliary MR imaging. First human experience with Mn-DPDP. Radiology 178 (1991), 79.
15. LIOU J., LEE J. K. T., BORRELLO J. A. & BROWN J. J.: Differentiation of hepatomas from nonhepatomatous masses. Use of MnDPDP-enhanced MR images. Magn. Reson. Imaging 12 (1994), 71.
16. MARCHAL G., NI Y., ZHANG X., YU J., LODEMANN K.-P. & BAERT A L.: Mn-DPDP enhanced MRI in experimental bile duct obstruction. J. Comput. Assist. Tomogr. 17 (1993), 290.
17. MARCHAL G., ZHANG X., NI Y., YU J. & BAERT A.: Comparison between Gd-DTPA, Gd-EOB-DTPA and Mn-DPDP in induced HCC in rats. A correlation study of MR imaging, microangiography and histology. Magn. Reson. Imaging 11 (1993), 665.
18. MISSELWITZ B., MÜHLER A. & WEINMANN H. J.: A toxicologic risk for using manganese complexes? A literature survey of existing data through several medical specialties. Invest. Radiol. 30 (1995), 611.
19. MÜHLER A., OUDE ELFERINK R. P. J. & WEINMANN H. J.: Complete elimination of the hepatobiliary MR contrast agent Gd-EOB-DTPA in hepatic dysfunction. An experimental study using transport-deficient, mutant rats. MAGMA 1 (1993), 134.
20. MURAKAMI T., BARON R., PETERSON M. S. et al.: Hepatocellular carcinoma. MR imaging with mangafodipir trisodium (Mn-DPDP). Radiology 200 (1996), 69.
21. NI Y., MARCHAL G., VAN DAMME B. et al.: MR imaging, microangiography and histology in a rat model of primary liver cancer. Invest. Radiol. 27 (1992), 689.
22. NI Y., MARCHAL G., YU J., MÜHLER A., LUKITO G. & BAERT A. L.: Prolonged positive enhancement by Gd-EOB-DTPA in experimental liver tumors. Potential value in tissue characterization. J. Magn. Reson. Imaging 4 (1994), 355.
23. NI Y., MARCHAL G., ZHANG X. et al.: The uptake of manganese dipyridoxal-diphosphate by chemically induced hepatocellular carcinoma in rats. A correlation between contrast-media-enhanced magnetic resonance imaging, tumor differentiation and vascularization. Invest. Radiol. 28 (1993), 520.
24. NI Y., PETRÉ C., LUKITO G. et al.: The effect of Mn-DPDP on liver MR imaging and serum bilirubin in rats with removable biliary obstruction. Acad. Radiol. 2 (1995), 300.
25. NI Y., LUKITO G., MARCHAL G. et al.: Potential role of bile duct collaterals in the recovery of the biliary obstruction. Experimental study in rats with microcholangiography, histology, serology and magnetic resonance imaging. Hepatology 20 (1994), 1557.
26. NI Y., MARCHAL G., YU J. et al.: Experimental liver cancers. Mn-DPDP-enhanced rims in MR-microangiographic-histologic correlation study. Radiology 188 (1993), 45.
27. 2. Acta Radiol. 38 (1997), 700.
28. ROCKLAGE S. M., CAAHERIS W. P., QUAY S. C., HAHN F. E. & RAYMOND K. N.: Manganese (II) N, N′-dipyridoxylethylen-ediamine-NN′-diacetate 5,5′-bis (phosphate). Synthesis and characterization of a paramagnetic chelate for magnetic resonance imaging enhancement. Inorg. Chem. 28 (1989). 477.
29. ROCKLAGE S. M. & VANWAGONER M.: Hepatobiliary contrast agents. An overview of the development of manganese dipyridoxyl diphosphate (MnDPDP). In: Liver imaging, p. 374. Edited by J. T. Ferrucci & D. D. Stark. Andover Medical, Boston 1990.
30. ROFSKY N. M., WEINREB J. C., BERNARDINO M. E., YOUNG S. W., LEE J. & NOZ M.: Hepatocellular tumors. Characterization with Mn-DPDP-enhanced MR imaging. Radiology 188 (1993), 53.
31. RUMMENY E., EHRENHEIM C., GEHL H. B. et al.: Manganese-DPDP as a hepatobiliary contrast agent in the magnetic resonance imaging of liver tumors. Results of clinical phase II trials in Germany including 141 patients. Invest. Radiol. 26 (1991), S142.
32. RUMMENY E., WIESMANN W., MENKER S., LODEMANN K. & PETER P. E.: Value of delayed Mn-DPDP enhanced MR imaging in the detection and differential diagnosis of hepatic tumors. J. Magn. Reson. Imaging 2 (1992), 65.
33. SARIC M.: Manganese. In: Handbook on the toxicology of metals, vol. 2, chapter 15, p. 354. Edited by L. Firebug et al. Elsevier Science Publishers B.V., Amsterdam 1986.
34. SIDHU M. K., MULLER H. H., AGGELER J., JONES A. L. & YOUNG S. W.: Manganese dipyridoxal diphosphate-enhanced magnetic resonance imaging in the evaluation of hepatocyte function. Invest. Radiol. 28 (1993), 903.
35. SOUTHON T. E., GRANT D., BJØRNERUD A. et al.: NMR relaxation studies with MnDPDP. Acta Radiol. 38 (1997), 708.
36. TANIMOTO A., KREFT B. P., BABA Y. et al.: Evaluation of hepatocyte-specific paramagnetic contrast media for MR imaging of hepatitis. J. Magn. Reson. Imaging 3 (1993), 786.
37. TOFT K. G., HUSTVEDT S. O., GRANT D. et al.: Metabolism and pharmacokinetics of MnDPDP in man. Acta Radiol. 38 (1997), 677.
38. TORRES C. G., LUNDBY B., TUFTE STERUD A., MCGILL S., GORDON P. B. & STRAND BJERKNES H.: MnDPDP for MR imaging of the liver. Results from the European phase III studies. Acta Radiol. 38 (1997), 631.
39. 6 and cancer. (Review.) Anticancer Res. 1 (1981), 263.
40. WITZLEBEN C. L.: Bilirubin as a cholestatic agent. Physiologic and morphologic observations. Am. J. Pathol. 62 (1971), 181.
41. YOUNG S. W., BRADLEY B., MULLER H. H. & RUBIN D. L.: Detection of hepatic malignancies using Mn-DPDP. Magn. Reson. Imaging 8 (1990), 367.
42. YOUNG S. W., SIMPSON B. B., RATNER A. V., MATKIN C. & CARTER E.: MRI measurement of hepatocyte toxicity using the new MRI contrast agent manganese dipyridoxal diphosphate, a manganese/pyridoxal-5-phosphate chelate. Magn. Reson. Med. 10 (1989), 1.